DDX54 Downregulation Enhances Anti-PD1 Therapy in Immune-Desert Lung Tumors with High Tumor Mutational Burden

Scientists identified DDX54 as a master regulator in immune-desert lung cancer with a high mutational burden, whose knockdown reduced resistance to immune checkpoint inhibitors.